SABCS: Combo Approaches Help Some Younger Breast CA Patients

December 12, 2014 1:12 AM

2 0

THURSDAY, Dec. 11, 2014 (HealthDay News) -- While tamoxifen plus ovarian suppression does not provide a significant benefit over tamoxifen alone among premenopausal women with hormone receptor-positive early breast cancer, the addition of ovarian suppression does benefit some of these women, and exemestane plus ovarian suppression further improves disease outcomes, according to new research. The findings were published online Dec. 11 in the New England Journal of Medicine to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 9 to 13 in San Antonio.

Prudence A. Francis, M.D., from the University of Melbourne in Australia, and colleagues examined the role of adjuvant ovarian suppression in hormone receptor-positive early breast cancer recurrence. The authors randomized 3,066 premenopausal women, classified according to prior receipt or nonreceip...

Read more

To category page

Loading...